Topical therapy with negative allosteric modulators of the calcium-sensing receptor (calcilytics) for the management of asthma: the beginning of a new era?

In this review article we present the evidence to date supporting the role of the calcium-sensing receptor (CaSR) as a key, pluripotential molecular trigger for asthma and speculate on the likely benefits of topical therapy of asthma with negative allosteric modulators of the CaSR: calcilytics.

Automated summary

This review article provides an overview of the evidence supporting the role of the calcium-sensing receptor (CaSR) as a key molecular trigger for asthma and discusses the potential benefits of using negative allosteric modulators of the CaSR, known as calcilytics, for topical therapy of asthma.